Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor used to treat chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Both MCL and CLL are B-cell non-Hodgkin's lymphomas, which are refractory and easy to relapse. Commonly used chemotherapy and immunotherapy are not targeted, and grade 3 or 4 adverse reactions often occur. Ibrutinib can be targeted to bind with BTK necessary for the formation, differentiation, information transmission and survival of B lymphocytes, irreversibly inhibit the activity of BTK, and effectively inhibit the proliferation and survival of tumor cells; and it is absorbed rapidly after oral administration, 1~ The maximum blood drug concentration reached 2 hours, and the adverse reaction is classified as 1 or 2, which will become a new choice for the treatment of CLL and MCL.
Audited Supplier 
){kind=link}